What type of study is this?

This is a Animal Study study (also classified as: In Vitro Study, Observational).

August 24, 2025Open Access

Ex vivo and in vivo CRISPR/Cas9 screenings identify the roles of protein N-glycosylation in regulating T-cell activation and functions

View Full Paper

Ask AI

Bookmark

Authors

CRISPR/Cas9 screenings identify B4GALT1's impact on T-cell activation in tumor immunotherapy, suggesting new therapy targets.

Inactivation of B4GALT1 enhances T-cell receptor activation and improves CD8+ T-cell functions, leading to better immunotherapy outcomes.
Affinity purification identified substrates of B4GALT1 on CD8+ T-cell surfaces, crucial for TCR and CD8 interaction.
Observational analysis shows B4GALT1 expression in tumor-infiltrated CD8+ T-cells correlates negatively with patient prognosis.
Suppressing B4GALT1 enhances TCR-T-cell functions but does not affect CAR-T cells, indicating a specific pathway for therapeutic targeting.

Hong et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

August 24, 2025Open Access

View Full Paper

Ask AI

Bookmark

Authors

CRISPR/Cas9 screenings identify B4GALT1's impact on T-cell activation in tumor immunotherapy, suggesting new therapy targets.

Inactivation of B4GALT1 enhances T-cell receptor activation and improves CD8+ T-cell functions, leading to better immunotherapy outcomes.
Affinity purification identified substrates of B4GALT1 on CD8+ T-cell surfaces, crucial for TCR and CD8 interaction.
Observational analysis shows B4GALT1 expression in tumor-infiltrated CD8+ T-cells correlates negatively with patient prognosis.
Suppressing B4GALT1 enhances TCR-T-cell functions but does not affect CAR-T cells, indicating a specific pathway for therapeutic targeting.

Hong et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark